Business

Heart Imaging Software Company Artrya (ASX: AYA) Makes Public Debut – The Market Herald

apply

The news that moves the market first

  • Artrya (AYA) was allowed to trade on the Australian Stock Exchange (ASX) with an AYA ticket after the initial public offering (IPO) was successfully completed.
  • The company began trading today with 78.2 million issued shares, generating a market capitalization of $ 105.6 million at an IPO price of $ 1.35.
  • The IPO has raised a total of $ 40 million with support from both current and new investors.
  • Artrya shares rose to just $ 1.51 each at the close of trading on Friday.

Artrya (AYA), an artificial intelligence medical technology business, began trading on ASX after its initial public offering (IPO) was successfully completed.

The company began trading today with over 78.2 million outstanding shares. It provided a market capitalization of $ 105.6 million based on an IPO price of $ 1.35 per share.

The IPO has raised a total of $ 40 million with support from both current and new investors.

John Barrington, Managing Director and Co-Founder of Artrya, said listing is an important milestone for the company and that investor support during the IPO is promising.

“This number is expected to increase in the coming decades, as 9 million people die each year from coronary artery disease worldwide and the aging population continues to put pressure on the healthcare system.” He said.

“This float helps us pursue further growth in the United States, United Kingdom, Canada, and Europe. We ensure that our shareholders are rewarded for their belief in innovative Australian business. We are enthusiastic about product development and market entry strategies. “

After the auction, Artrya was recently appointed to the United Kingdom National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms, as disclosed in Artrya’s Perspective.

Artrya is one of the selected, prioritized and pre-certified candidate lists of approved suppliers to which various public agencies, including 1250 NHS hospitals, can contract services under the NHS SBS Framework Agreement. It is one.

Artrya’s core product, Salix, is an AI-based solution that analyzes heart CT images to detect unique combinations of heart attack indicators.

Salix assists clinicians in early detection of coronary artery disease and enables first-time correct treatment by highlighting the location and severity of the disease with 3D cardiac images and providing detailed patient reports in about 15 minutes. To.

Market pilots for Artrya’s Salix Coronary Anatomy (SCA) products are currently underway in Australia, and many pilot projects may move to commercial use in the first half of 2022.

Artrya shares rose to just $ 1.51 each at the close of trading on Friday.



Heart Imaging Software Company Artrya (ASX: AYA) Makes Public Debut – The Market Herald

Source link Heart Imaging Software Company Artrya (ASX: AYA) Makes Public Debut – The Market Herald

Related Articles

Back to top button